Nuance Investments’s Bioventus BVS Stock Holding History

Nuance Investments’s Portfolio BVS Stock Details BVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-600,147	Closed	-$4.09M	–	56
2022 Q2	$4.09M	Sell	600,147 -751,954	-56%	-$7.67M	0.08%	47
2022 Q1	$19.1M	Buy	1,352,101 +77,061	+6%	+$1.03M	0.34%	39
2021 Q4	$18.5M	Buy	1,275,040 +123,283	+11%	+$1.75M	0.33%	39
2021 Q3	$16.3M	Buy	1,151,757 +454,907	+65%	+$7M	0.3%	41
2021 Q2	$12.3M	Buy	+696,850	New	+$11.2M	0.22%	49

Other funds holding BVS

EWM

Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return

JIC

Juniper Investment Company New York $378M AUM 95.37% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Nuance Investments's BVS Position: Q3 2022 in Review

Nuance Investments sold out of Bioventus (BVS) in Q3 2022, closing a stake of 600,147 shares — an estimated $4.09M sold.

Nuance Investments first reported a position in BVS in Q2 2021 and held it in 5 quarters. The position peaked at $19.1M in Q1 2022. 94 funds tracked by Wall St. Rank hold BVS as of Q3 2022.

Nuance Investments reported no remaining Bioventus position as of Q3 2022 after selling out during the quarter.
Nuance Investments sold 600,147 Bioventus shares in Q3 2022, an estimated $4.09M.
Nuance Investments first reported a position in Bioventus in Q2 2021 and held it in 5 quarters.
Nuance Investments's Bioventus position peaked at $19.1M in Q1 2022.
94 funds tracked by Wall St. Rank held Bioventus as of Q3 2022.

Based on Nuance Investments's 13F filing for Q3 2022, filed 10 Nov 2022.